Relationship of troponins with in-hospital mortality in adults with covid-19 in a colombian caribbean city: a nested case-control study

Maria C. Ospino-Guerra; Carlos H. Murgas-Cañas; Jessica L. Ospino-Guzman; Lourdes Varela-Prieto; Rodolfo Cano-Rivera; Rusvelt Vargas-Moranth

doi:10.54034/mic.e1940

Authors

Maria C. Ospino-Guerra Universidad Libre seccional Barranquilla, Colombia https://orcid.org/0000-0003-1457-6038
Carlos H. Murgas-Cañas Universidad Libre seccional Barranquilla, Colombia
Jessica L. Ospino-Guzman Universidad Libre seccional Barranquilla, Colombia https://orcid.org/0000-0002-1021-8287
Lourdes Varela-Prieto Universidad Libre seccional Barranquilla, Colombia
Rodolfo Cano-Rivera Universidad Libre seccional Barranquilla, Colombia
Rusvelt Vargas-Moranth Universidad Libre seccional Barranquilla, Colombia https://orcid.org/0000-0002-1014-0969

DOI:

https://doi.org/10.54034/mic.e1940

Keywords:

COVID-19, mortality, troponins, predictive value, myocardial injury

Abstract

Background: myocardial injury, characterized by elevated cardiac troponin levels, is a common finding in severe COVID-19 cases, occurring in up to 38% of patients. It has been identified as an independent predictor of mortality. Objective: our aim is to assess the predictive value of cardiac troponin levels for in-hospital mortality among adults hospitalized with COVID-19 in Barranquilla, Colombia, during the period from January to June 2021. Methods: this study is a nested case-control analysis within a retrospective cohort. It encompasses individuals aged 18 and older with a confirmed diagnosis of COVID-19 who were hospitalized between January and June 2021 (n = 358). We describe the demographic and paraclinical characteristics of the patients and their association with outcomes at the time of discharge. We also estimate the diagnostic accuracy, including sensitivity, specificity, and predictive values, of elevated troponin levels in predicting in-hospital mortality. Results: patients with elevated troponin levels demonstrated a significantly increased risk of in-hospital mortality (OR: 9.4; 95% CI: 5.5-16.0; p < 0.05) and had a notably higher in-hospital mortality rate (55.6%) compared to those with non-elevated troponin levels (11.7%). The troponin biomarker exhibited a sensitivity of 77.9% and specificity of 72.7%, with positive and negative predictive values of 55.6% and 88.3%, respectively, for in-hospital mortality. Conclusion: troponin elevation in subjects with COVID-19 is positively related to in-hospital mortality, independently of other conditions such as age group, comorbidities, or oxygen therapy requirement.

References

Woodall MNJ, Masonou T, Case KM, Smith CM. Human models for COVID-19 research. J Physiol. 2021; 599(18): 4255–67.

Gautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, et al. Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol. 2020; 16(12): 1159–84.

Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–25.

Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2020;92(10):1875–83.

Zinellu A, Sotgia S, Fois AG, Mangoni AA. Serum CK-MB, COVID-19 severity and mortality: An updated systematic review and meta-analysis with meta-regression. Adv Med Sci. 2020;66(2):304–14.

McKinney J, Connelly KA, Dorian P, Fournier A, Goodman JM, Grubic N, et al. COVID-19–Myocarditis and Return to Play: Reflections and Recommendations From a Canadian Working Group. Can J Cardiol. 2021;37(8):1165–74.

Deng P, Ke Z, Ying B, Qiao B, Yuan L. The diagnostic and prognostic role of myocardial injury biomarkers in hospitalized patients with COVID-19. Clin Chim Acta [Internet]. 2020;510:186–90. Available from: https://doi.org/10.1016/j.cca.2020.07.018

Junior GLG de A, Braga F, Jorge JK, Nobre GF, Kalichsztein M, de Faria P de MP, et al. Prognostic value of troponin-t and b-type natriuretic peptide in patients hospitalized for covid-19. Arq Bras Cardiol. 2020;115(4):660–6.

Thygesen K, Jaffe AS, Chaitman BR, White HD, Zealand N, Canada PJD. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231–64.

Vélez M, Velásquez P, Acosta J, Vera C, Santiago J, Jimenez C, et al. Factores clínicos pronósticos de enfermedad grave y mortalidad en pacientes con COVID-19. Univ Antioquia [Internet]. 2020;1(1):57. Available from: http://fi-admin.bvsalud.org/document/view/rpncv NS -

Mesas AE, Cavero-Redondo I, Álvarez-Bueno C, Cabrera MAS, de Andrade SM, Sequí-Dominguez I, et al. Predictors of in-hospital COVID-19 mortality: A comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions. PLoS One. 2020;15(11 November):1–23.

Moutchia J, Pokharel P, Kerri A, McGaw K, Uchai S, Nji M, et al. Clinical laboratory parameters associated with severe or critical novel coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. PLoS One [Internet]. 2020; 15(10 October): 1–25. Available from:

http://dx.doi.org/10.1371/journal.pone.0239802

Ghahramani S, Tabrizi R, Lankarani KB, Kashani SMA, Rezaei S, Zeidi N, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: A systematic review and meta-analysis. Eur J Med Res [Internet]. 2020;25(1):1–10. Available from: https://doi.org/10.1186/s40001-020-00432-3

Ali AM, Rostam HM, Fatah MH, Noori CM, Ali KM, Tawfeeq HM. Serum troponin, D-dimer, and CRP level in severe coronavirus (COVID-19) patients. Immunity, Inflamm Dis. 2022;10(3):1–10.

Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis. 2020; 95(January): 304–7.

Malik P, Patel U, Patel NH, Somi S, Singh J. Elevated cardiac troponin i as a predictor of outcomes in covid-19 hospitalizations: A meta-analysis. Infez Med. 2020; 28(4): 500–6.

Papageorgiou N, Sohrabi C, Prieto Merino D, Tyrlis A, Atieh AE, Saberwal B, et al. High sensitivity troponin and COVID-19 outcomes. Acta Cardiol [Internet]. 2022;77(1):81–8. Available from:

https://doi.org/10.1080/00015385.2021.1887586

Stefanini GG, Chiarito M, Ferrante G, Cannata F, Azzolini E, Viggiani G, et al. Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart. 2020;106(19):1512–8.

Metkus TS, Sokoll LJ, Barth AS, Czarny MJ, Hays AG, Lowenstein CJ, et al. Myocardial Injury in Severe COVID-19 Compared with Non-COVID-19 Acute Respiratory Distress Syndrome. Circulation. 2021;553–65.

Ghio S, Montalto C, Pagnesi M, Lupi L, Cappelletti A, Baldetti L, et al. High troponin levels in patients hospitalized for coronavirus disease 2019: a maker or a marker of prognosis? J Cardiovasc Med (Hagerstown). 2021; 22(11): 828–31.

Zhu F, Li W, Lin Q, Xu M, Du J, Li H. Myoglobin and troponin as prognostic factors in patients with COVID-19 pneumonia. Med Clin (Barc). 2021;157(January):164–71.

Al B, Torres P, Ramos-tuarez F, Dewaswala N, Abdallah A. Cardiac Troponin-I and COVID-19 : A Prognostic Tool for In-Hospital Mortality. 2020;11(6):398–404.

Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci [Internet]. 2020;0(0):389–99. Available from:

https://doi.org/10.1080/10408363.2020.1770685

Imazio M, Klingel K, Kindermann I, Brucato A, De Rosa FG, Adler Y, et al. COVID-19 pandemic and troponin: Indirect myocardial injury, myocardial inflammation or myocarditis? Heart. 2020;106(15):1127–31.